AICAR Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 8 weeks on, 4 weeks off minimum; extended protocols run 8 to 12 weeks; 2 to 3 cycles per year maximum
• Frequency: Once daily subcutaneous injection; some practitioners apply a 5-days-on, 2-days-off cadence
• Common delivery routes: Subcutaneous injection (primary research route)
• Key timing notes: Consistent daily timing matters more than clock precision; pre-workout administration is commonly cited when training is part of the protocol

Who This Protocol Is For

AICAR sits in a narrow, distinct corner of the research peptide space. Its mechanism reaches into cellular energy regulation, which is why endurance athletes and metabolic researchers are its main audience. It is an AMPK activator, meaning it works by mimicking the signal that tells cells to switch into energy-burning mode, and the people who research it are usually drawn by one of two things: endurance performance and metabolic health.

The first group is endurance-focused athletes and researchers, runners, cyclists, and similar athletes who have encountered AICAR through the exercise-mimetic research. The rodent data showing meaningful gains in running endurance in sedentary mice put AICAR on the radar of anyone interested in aerobic capacity, and that interest has persisted in biohacking circles for years. This group tends to run AICAR alongside an active training program, treating it as a potential amplifier rather than a substitute for training.

The second group is metabolic-health focused. People researching insulin sensitivity, glucose regulation, and fat oxidation are drawn to AICAR's mechanism because AMPK activation sits at the intersection of all three. Those who have not responded as expected to lifestyle interventions alone, or who are researching compounds that work independently of insulin signaling, often explore AICAR as part of that picture.

Experience level matters here more than it does for many peptides. AICAR carries a meaningful safety profile, and a titration structure is not optional. This is not a compound that rewards jumping straight to a high dose on day one. Researchers who have already run simpler peptide protocols and understand titration discipline, monitoring, and cycling principles are better positioned than complete newcomers.

Delivery method is not a question with AICAR in the same way it is with some other research compounds. The primary research route is subcutaneous injection. There is no oral, sublingual, or nasal protocol with meaningful data behind it.

How Is an AICAR Cycle Structured?

The standard AICAR cycle runs eight weeks and follows a stepped titration shape rather than a flat dose from day one. Think of it as a ramp: the body gets time to adjust at each level before stepping up to the next. The cycle moves through an initiation and titration phase in the first four weeks, then a target-dose phase in weeks five through eight.

After the eight weeks, a four-week off-cycle break is standard before any repeat cycle. Most protocols cap total annual use at two to three cycles. Extended protocols can stretch to twelve weeks before the break, with a correspondingly longer washout period recommended afterward.

There are no formally defined loading and maintenance phases for AICAR in the clinical sense. What the research and practitioner community has converged on instead is a titration structure: starting low enough to establish tolerability, then stepping up to the target range in increments. The off-cycle break is the other structural pillar, included specifically because chronic continuous AMPK activation carries risks that cycling is designed to mitigate. Both phases are covered in full detail in the Loading and Maintenance Phases section below.

How Your Dose Is Determined

What moves an AICAR dose:

• Your goal: AICAR is researched for two broadly different purposes, and the dose shifts between them. Endurance and aerobic performance research trends toward the higher end of the range, where the exercise-mimetic effect in animal models was most pronounced. Metabolic research, including insulin sensitivity and fat oxidation work, may sit toward the lower end. Both goals still start at the same low initiation point and titrate up based on response.
• Experience level: A first-time AICAR researcher starts at the lowest titration point, always. Someone who has run a prior cycle and established their tolerability picture has more data to inform how far up the range to step. The titration structure is not optional for either group, but where within the range someone lands is informed by prior experience.
• Individual response: AICAR's side-effect profile, particularly the kidney and glucose signals, means individual response is not a secondary consideration. How someone's body handles the compound at each titration step determines whether the next step is appropriate. Two researchers with the same goal can land at different points based on how they respond.
• Titration cadence: The dose increases in increments, with each step held for roughly two weeks before moving up. That cadence is itself part of the protocol design. Skipping steps to reach the target faster is one of the clearest mistakes in AICAR research and is covered in the mistakes section.

There is no universal target that fits every researcher, every goal, or every body. The range spans meaningfully from initiation through the upper end of extended protocols, and where someone lands within that range is a function of everything above. The two-week hold at each step is explained in full in the Loading and Maintenance Phases section.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal, your experience with AICAR or similar AMPK-activating compounds, and your individual response at each titration step and builds your AICAR protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take AICAR?

The standard frequency is once daily, seven days per week, administered via subcutaneous injection. This daily cadence reflects the compound's relatively short action window and the goal of maintaining consistent AMPK activation across the cycle rather than achieving peaks and troughs.

Some practitioners apply a five-days-on, two-days-off schedule, a Monday-through-Friday pattern borrowed from general peptide cycling principles to protect receptor sensitivity over a long cycle. This approach is not specifically validated for AICAR; it has been adapted from principles applied to other compounds and some researchers prefer it on those general grounds.

Timing within the day matters less than consistency. Pre-workout administration is the most commonly cited approach among researchers pairing AICAR with active training, with the logic being that timing the dose thirty to sixty minutes before exercise may align the compound's metabolic effects with the training window. For researchers not combining AICAR with a structured exercise program, any consistent daily time works. What does not work is erratic timing: varying the injection time day to day disrupts the metabolic rhythm the protocol is designed to establish.

Loading and Maintenance Phases

AICAR does not use a traditional loading phase where the first week or two involves a higher or front-loaded dose to saturate the system quickly. The structure here runs in the opposite direction: the lowest point in the cycle is the start.

What exists instead is a titration-then-hold shape. The first two weeks function as the initiation period, where the dose is at its lowest and the primary purpose is establishing tolerability and allowing the body to begin adjusting to AMPK activation. The next two weeks step the dose up. By weeks five through eight, the dose has reached its target and holds there, which is the closest thing this protocol has to a maintenance phase.

The dose stays consistent within each two-week window. There is no separate loading number that is higher than the target, and no separate maintenance number that is lower. Every step is an increase, and the target phase is simply holding the highest point the researcher has reached. The dose across loading and maintenance is consistent within each phase; what changes is the step from one phase to the next.

This structure matters because the side-effect profile, particularly the kidney and glucose signals, makes it genuinely important to establish how someone responds at each level before adding more. The two-week hold at each step is the mechanism by which the protocol stays responsive to the individual rather than running a fixed program regardless of how the body is handling the compound.

Extended protocols that continue beyond eight weeks hold the target dose rather than stepping higher, unless specific monitoring and rationale are in place.

Off-Cycle Considerations

The off-cycle break is not optional for AICAR. A minimum four-week break after each cycle is the consistent recommendation across practitioner protocols, and the rationale is grounded in the compound's mechanism rather than a general peptide cycling principle.

Chronic AMPK activation carries risks that accumulate with continuous use. Extended AMPK activation has been associated with brain inflammation in preclinical models. That is one of the clearest arguments for cycling rather than running AICAR continuously. There are also oncological concerns associated with high sustained doses over long periods. Those concerns are another reason protocols built around this compound cap continuous use at roughly three months or less.

The four-week minimum break allows metabolic pathways to reset and reduces the cumulative risk that comes with sustained AMPK activation. Extended twelve-week cycles call for a correspondingly longer washout, sometimes six to eight weeks, before beginning again. The annual ceiling of two to three cycles is as important as the per-cycle break; stacking cycles with minimal off time defeats the purpose of cycling entirely.

During the off-cycle period, researchers who monitored kidney function and blood glucose during the cycle should continue checking those markers in the first weeks after stopping.

What to Expect Week by Week

The honest framing here is that human experience data for AICAR is sparse and largely anecdotal. The animal research is more defined, but animal-to-human translation has not been established in controlled trials. What follows reflects both what the animal data suggests and what the research community has reported informally, with that distinction kept clear.

• Week 1 to 2: This is the initiation period at the lowest dose. The primary purpose of this window is tolerability, not effect. Some researchers report mild increases in perspiration and a subtle shift in workout energy, but definitive effects at this stage are uncommon.
• Week 3 to 4: The dose steps up and the protocol enters its titration window. A fourteen-day mouse study found clear changes in key energy-regulation proteins, including AMPK and ACC (acetyl-CoA carboxylase, an enzyme that controls fat storage), as well as shifts in insulin and glucose measures, by the end of this period. In the research community, some users report broader energy and endurance sensations beginning around this window, though these are informal and uncontrolled reports.
• Week 5 to 8: The target-dose phase. Animal research found a roughly forty percent increase in treadmill running endurance in sedentary mice across a comparable window. Whether that translates to humans at subcutaneous research doses has not been established in trials. This is, however, the window where researchers who pair AICAR with consistent training and reach their target dose give the compound's exercise-mimetic mechanism its best opportunity to express itself. Among those who do report meaningful effects, this phase is consistently when they describe them most clearly, with endurance output and metabolic markers being the most commonly noted improvements.
• Beyond 8 weeks: Extended protocols hold the target dose. The risk picture accumulates with time, which is why these longer runs require closer monitoring and a longer washout afterward.

Individual results vary significantly based on dose level reached, consistency, training volume, and baseline metabolic state. These timelines are orientation, not prediction.

Common Protocol Mistakes

Missing a dose and doubling the next one. This is the single most consistently flagged mistake across every AICAR protocol. A missed injection is a missed dose, not a deficit to make up. Doubling introduces exactly the kind of spike in AMPK activation the titration structure is designed to avoid. Note it in the log and continue with the next scheduled dose.

Skipping titration. The impulse to jump to the target range immediately is understandable but genuinely risky. Starting at the lowest point and holding each step for two weeks before moving up is not a slow-play suggestion; it is how the protocol stays safe and responsive. Starting at the top is one of the clearest ways to produce adverse effects that would not have appeared under a proper titration.

Inconsistent injection timing. Varying the time of day disrupts the metabolic rhythm the protocol is designed to maintain. Pick a consistent time, document it, and hold it across the cycle.

Ignoring kidney monitoring. Baseline kidney function before starting, and periodic checks during the cycle, is a reasonable practice for anyone running AICAR. The nephrotoxicity signal from cardiac surgery trial data was at high intravenous doses in compromised patients, but the signal exists and ignoring it entirely is not the right response.

Failing to monitor blood glucose. AICAR increases glucose uptake independent of insulin. Hypoglycemia is a real risk, particularly in fasted states or when other glucose-lowering agents are in the picture. Researchers should be aware of how blood sugar responds, especially at each new titration step.

Skipping the off-cycle break. Running AICAR continuously bypasses the logic that makes the cycle structure protective. The neurological signals and oncological concerns associated with sustained high-dose chronic use are the reason the break exists.

Sourcing from unverifiable suppliers. The quality and purity of AICAR as a research compound vary significantly across the supplier landscape. Contamination and mislabeled concentrations are real risks. Researchers prioritize suppliers with transparent manufacturing standards and independent third-party testing results.

Frequently Asked Questions

How long is a typical AICAR cycle?

The standard AICAR cycle runs eight weeks, following a titration structure that steps the dose up every two weeks before holding at the target for the final weeks. Extended protocols can run eight to twelve weeks. After each cycle, a minimum four-week off-cycle break is standard, and most protocols limit annual use to two to three cycles.

How often do you take AICAR?

AICAR is dosed once daily via subcutaneous injection in standard research protocols. Some practitioners use a five-days-on, two-days-off schedule borrowed from general peptide cycling principles, though this is not specifically validated for AICAR. Consistent timing each day matters more than the exact clock time, with pre-workout administration being the most commonly cited option among researchers who pair AICAR with training.

Does AICAR need a loading phase?

No, not in the conventional sense. AICAR does not front-load with a higher initial dose. The cycle begins at its lowest point and titrates up incrementally over the first four weeks, which is distinct from a traditional loading phase designed to saturate the system quickly.

Do you need to cycle off AICAR?

Yes, and the break is more than a general peptide principle here. Chronic AMPK activation carries specific risks, including neurological signals associated with extended use in preclinical models. A minimum four-week break after each cycle is standard, with longer washouts recommended after extended twelve-week runs.

Is AICAR safe to combine with other compounds?

Combination research with AICAR carries meaningful caution. Other AMPK activators can produce unpredictable activation levels when stacked, and insulin or insulin-sensitizing agents present a hypoglycemia risk given AICAR's independent effect on glucose uptake. Any combination involving AICAR warrants careful consideration and, where possible, oversight from someone familiar with the compound's mechanism.

What does WADA prohibition mean for athletes researching AICAR?

It means competitive athletes subject to anti-doping rules cannot use AICAR under any circumstances. The prohibition applies both in-competition and out-of-competition, with no Therapeutic Use Exemption pathway because the compound has no approved therapeutic human use anywhere in the world. A positive test carries sanctions with no exemption route available.

Regulatory Status

AICAR is not approved for human therapeutic use anywhere in the world. It has been prohibited by WADA under the category of hormone and metabolic modulators since 2009, banned both in-competition and out-of-competition, with no Therapeutic Use Exemption pathway available.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for AICAR in one place.